These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33293671)

  • 41. Management of unresectable stage III non-small cell lung cancer: the role of combined chemoradiation.
    Penland SK; Socinski MA
    Semin Radiat Oncol; 2004 Oct; 14(4):326-34. PubMed ID: 15558508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
    Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trends and variations in the treatment of stage I-III small cell lung cancer from 2008 to 2019: A nationwide population-based study from the Netherlands.
    Evers J; Hendriks LEL; De Jaeger K; Wijsman R; De Ruysscher D; Terhaard C; van der Sangen M; Siesling S; Struikmans H; Aarts MJ
    Lung Cancer; 2021 Dec; 162():61-70. PubMed ID: 34739855
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of daily carboplatin plus irradiation followed by durvalumab for stage III non-small cell lung cancer patients with PS 2 up to 74 years old and patients with PS 0 or 1 from 75 years: NEJ039A (trial in progress).
    Kaira K; Mouri A; Kato S; Yoshimura K; Kagamu H; Kobayashi K
    BMC Cancer; 2020 Oct; 20(1):961. PubMed ID: 33023530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer.
    Vokes EE; Crawford J; Bogart J; Socinski MA; Clamon G; Green MR
    Clin Cancer Res; 2005 Jul; 11(13 Pt 2):5045s-5050s. PubMed ID: 16000612
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
    Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
    Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Induction chemotherapy with cetuximab, vinorelbine-cisplatin followed by thoracic radiotherapy and concurrent cetuximab, vinorelbine-cisplatin in patients with unresectable stage III non-small cell lung cancer.
    Liu D; Zheng X; Chen J; Liu G; Xu Y; Shen Y; Xie L; Zhao W; Jiang G; Fan M
    Lung Cancer; 2015 Sep; 89(3):249-54. PubMed ID: 26118463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712.
    Davies AM; Chansky K; Lau DH; Leigh BR; Gaspar LE; Weiss GR; Wozniak AJ; Crowley JJ; Gandara DR;
    J Clin Oncol; 2006 Nov; 24(33):5242-6. PubMed ID: 17114656
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemoradiotherapy for lung cancer: current status and perspectives.
    Ohe Y
    Int J Clin Oncol; 2004 Dec; 9(6):435-43. PubMed ID: 15616873
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Benefit of Concurrent Versus Sequential Chemoradiotherapy in Elderly Patients With Stage III Non-Small Cell Lung Cancer.
    Logtenberg ME; Tomlow B; Kastelijn EA; Schramel FMNH
    Clin Lung Cancer; 2022 Mar; 23(2):116-121. PubMed ID: 35042652
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Induction and concurrent chemotherapy with high-dose thoracic conformal radiation therapy in unresectable stage IIIA and IIIB non-small-cell lung cancer: a dose-escalation phase I trial.
    Socinski MA; Morris DE; Halle JS; Moore DT; Hensing TA; Limentani SA; Fraser R; Tynan M; Mears A; Rivera MP; Detterbeck FC; Rosenman JG
    J Clin Oncol; 2004 Nov; 22(21):4341-50. PubMed ID: 15514375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase I trial of concurrent thoracic radiation and continuous infusion cisplatin and etoposide in stage III non-small cell lung cancer.
    Kalemkerian GP; Belzer K; Wozniak AJ; Gaspar LE; Valdivieso M; Kraut MJ
    Lung Cancer; 1999 Sep; 25(3):175-82. PubMed ID: 10512128
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
    Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
    Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase II trial of combined modality therapy with concurrent topotecan plus radiotherapy followed by consolidation chemotherapy for unresectable stage III and selected stage IV non-small-lung cancer.
    Seung SK; Ross HJ
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):802-9. PubMed ID: 18762390
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of conformal radiotherapy technique on survival after chemoradiotherapy for patients with stage III non-small cell lung cancer in the National Cancer Data Base.
    Sher DJ; Koshy M; Liptay MJ; Fidler MJ
    Cancer; 2014 Jul; 120(13):2060-8. PubMed ID: 24692108
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812).
    Maggiore RJ; Zahrieh D; McMurray RP; Feliciano JL; Samson P; Mohindra P; Chen H; Wong ML; Lafky JM; Jatoi A; Le-Rademacher JG
    J Geriatr Oncol; 2021 May; 12(4):563-571. PubMed ID: 32950428
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report.
    Ratanatharathorn V; Lorvidhaya V; Kraipiboon P; Sirachainan E; Maoleekoonpairoj S; Phromratanapongse P; Cheirsilpa A; Tangkaratt S; Srimuninnimit V; Pattaranutaporn P; Lertsanguansinchai P
    J Med Assoc Thai; 2000 Jan; 83(1):85-92. PubMed ID: 10710874
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.
    Lee SW; Choi EK; Lee JS; Lee SD; Suh C; Kim SW; Kim WS; Ahn SD; Yi BY; Kim JH; Noh YJ; Kim SS; Koh Y; Kim DS; Kim WD
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):996-1004. PubMed ID: 12829135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.